4-MeO-PCP Stats & Data

4-MeO-PCP was originally synthesized in 1965 by Victor Maddox, a medicinal chemist working at the pharmaceutical company Parke-Davis. The compound remained largely obscure for decades following its initial creation. Interest in 4-MeO-PCP resurfaced in the late 1990s when a chemist writing under the pseudonym John Q. Beagle published a 1999 review suggesting that the substance possessed reduced potency compared to its parent compound PCP. In 2001, Beagle followed this with a more comprehensive publication detailing the synthesis procedure and describing the qualitative effects, estimating its potency at approximately 70% that of PCP. The compound holds a notable place in the history of online research chemical markets as the first arylcyclohexylamine to be sold through internet vendors. It was introduced to the market in late 2008 by a supplier operating under the name CBAY. This marked the beginning of a wave of related dissociative compounds entering the research chemical scene, with 3-MeO-PCP and methoxetamine (MXE) following shortly thereafter.

Forked from Subjective Effect Documentation work by Josie Kins, August 2016. Via dose.wiki (CC0).

The toxicity and long-term health effects of recreational 4-MeO-PCP use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 4-MeO-PCP has very little history of human usage. Anecdotal evidence from people who have tried 4-MeO-PCP within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this drug.

Effects aggregated from 7 experience reports (7 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 7 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

From 10 of 13 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most common forms and preparations, as a share of the 4 reports that give one

Too few reports for bars: these forms come from 4 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• Powder / Crystals 3 of 4